Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by
the loss of upper and lower motor neurons. Presently, three FDA-approved drugs are …

Blood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic
accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in …

Increasing appreciation of the phenotypic and biological overlap between amyotrophic
lateral sclerosis (ALS) and frontotemporal dementia, alongside evolving biomarker evidence …

Frontotemporal dementia (FTD) therapy development is hamstrung by a lack of
susceptibility, diagnostic, and prognostic biomarkers. Blood neurofilament light (NfL) shows …

Background Hexanucleotide repeat expansion of C9orf72 is a common genetic cause of
amyotrophic lateral sclerosis (ALS). No C9orf72-targeted treatments are available. BIIB078 …

A summit held March 2023 in Scottsdale, Arizona (USA) focused on the intronic
hexanucleotide expansion in the C9ORF72 gene and its relevance in frontotemporal …

Neurological biomarkers are particularly valuable to clinicians as they can be used for
diagnosis, prognosis, or response to treatment. This field of neurology has evolved …

Biomarkers for amyotrophic lateral sclerosis : Current Opinion in Neurology Biomarkers for
amyotrophic lateral sclerosis : Current Opinion in Neurology Log in or Register Subscribe to …

Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal dementia (FDT) are progressive
neurodegenerative disorders that, in several cases, overlap in clinical presentation, and …

Unlike familial Alzheimer's disease, we have been unable to accurately predict symptom
onset in presymptomatic familial frontotemporal dementia (f-FTD) mutation carriers, which is …